Following the approval of Aflibercept 8mg, clinicians in Europe now have 5 anti-VEGF treatments to choose from, not to mention biosimilars. How should we treat patients with so many options open to us? Sandrine Zweifel (Switzerland) and Stela Vujosevic (Italy) compare notes.
Members can continue the conversation in the EURETINA Forum.
Browse all podcast episodes here.
Listen on your preferred podcast player:
Listen on your preferred podcast player: